5:32
Dr. Justin Marson discusses a systematic review on the efficacy of rituximab in treating Epidermolysis Bullosa Acquisita (EBA). The study reveals that 92% of EBA patients achieved remission with rituximab, highlighting its potential as a non-steroidal treatment option. Key takeaways include the promising results of rituximab, the necessity for more extensive clinical research, and the hope for developing targeted therapies for EBA.
Produced with Vocal Video